- /
- Supported exchanges
- / US
- / UNCY.NASDAQ
Unicycive Therapeutics Inc (UNCY NASDAQ) stock market data APIs
Unicycive Therapeutics Inc Financial Data Overview
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Unicycive Therapeutics Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Unicycive Therapeutics Inc data using free add-ons & libraries
Get Unicycive Therapeutics Inc Fundamental Data
Unicycive Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -29 931 000
- Earnings Per Share: -2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
Get Unicycive Therapeutics Inc Earnings data
Corporate Events Calendar & News package for
What’s included:
- Latest Release: 2026-05-12
- EPS/Forecast: -0.472
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Unicycive Therapeutics Inc News
New
UNCY: Unicycive Therapeutics Investors with Losses Should Contact Block & Leviton About Securities Fraud Investigation
BOSTON, July 13, 2026 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Unicycive Therapeutics, Inc. (Nasdaq: UNCY) for potential securities law violations. Investors who have lost money in their...
UNCY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Unicycive Therapeutics, Inc.
NEW YORK, July 10, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ:...
UNCY SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
NEW YORK, July 06, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”...
Bragar Eagel & Squire, P.C. is Investigating Unicycive Therapeutics, Inc. on Behalf of Unicycive Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Unicycive (UNCY) To Contact Him Directly To Discuss Their Options If you purchased or acquire...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.